Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer



Status:Active, not recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 120
Updated:3/24/2019
Start Date:September 12, 2008
End Date:April 15, 2021

Use our guide to learn which trials are right for you!

A Phase II Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients With Node Negative, Peripheral Non-Small Cell Lung Cancer

RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the
tumor and cause less damage to normal tissue. It is not yet known which regimen of radiation
therapy is more effective in treating patients with non-small cell lung cancer.

PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy
regimens and to see how well they work in treating patients with stage I or stage II
non-small cell lung cancer.

OBJECTIVES:

Primary

- To compare the incidence of toxicity with two established stereotactic body radiotherapy
(SBRT) regimens in patients with node-negative, peripheral stage I or II non-small cell
lung cancer.

Secondary

- To compare quality of life, patterns of failure, disease-free survival, and overall
survival of these patients after treatment with one of two established SBRT regimens.

- To correlate outcomes and toxicities with imaging and patient and tumor biomarkers.

OUTLINE: Patients are stratified according to Karnofsky performance status and treatment
center. Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).

- Arm II: Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.

Quality of life is assessed periodically by the EORTC QLQ-C30 and -LC13 questionnaires

Blood and tissue samples may be collected periodically and examined for biomarkers via ELISA
and immunoblotting.

After completion of study treatment, patients are followed for 5 years.

Inclusion Criteria:

- Histologically confirmed non-small cell lung cancer

- T1-T2, N0 disease measuring ≤ 5 cm( T3 tumor based on chest wall involvement is
Excluded)

- Surgically resectable primary disease, however patient evaluated by thoracic
oncologist and deemed medically inoperable OR patient refuses surgical resection

- Age >= 18

Exclusion Criteria:

- Prior thoracic radiation therapy

- T2 or T3 tumor greater than 5 cm or T3 tumor based on chest wall involvement

- Node positive or metastatic disease

- Tumor location within the zone of the proximal bronchial tree. The proximal bronchial
tree is defined as the carina, right and left main bronchi, right and left upper lobe
bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, and
right and left lower lobe bronchi. The zone of the proximal bronchial tree is defined
as a volume 2cm in all directions around the proximal bronchial tree.

- No other conditions deemed by the PI or associates to make the patient ineligible for
protocol investigations, procedures, and high-dose external beam radiotherapy (e.g.,
unable to lie still and breathe reproducibly)

- Pregnant or unwilling to use adequate contraception
We found this trial at
3
sites
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
750 East Adams Street
Syracuse, New York 13210
?
mi
from
Syracuse, NY
Click here to add this to my saved trials